Corneal crosslinking in keratoconus management

Since two decades, corneal crosslinking (CXL) has been proposed as the sole therapeutic option to halt progression of keratoconus or other ectatic diseases. CXL aims at stiffening the cornea using a combination of ultraviolet-A light and a chromophore (vitamin B2, riboflavin), and has been proposed in various indications, from progressive ectatic diseases to comeal infec- tion. Despite being in clinical use for many years, many controversies and discrepancies exist towards CXL procedure and its exact rote is still under debate. We report an up-to-date review of the state of the art of CXL and describe the basic principles, the different existing CXL techniques reporting basic and clinical evidence, as welt as the new perspectives and the possible future developments of the procedure. (C) 2020 Elsevier Masson SAS. All rights reserved.